Carebot, a Central European leader in medical imaging and artificial intelligence, and global biopharmaceutical company Bristol Myers Squibb announce a collaboration aimed at improving early detection of lung cancer. This innovative partnership will enable the integration of Carebot, a solution that assists physicians in evaluating X-ray images, to increase diagnostic accuracy and accelerate the identification of early-stage lung cancer.
"We are very pleased to have partnered with Bristol Myers Squibb on this pivotal project," says Daniel Kvak, CEO of Carebot. "Our AI can contribute significantly to earlier detection of lung cancer, when the treatment is most effective. Together with Bristol Myers Squibb, we aim to transform the way lung cancer is diagnosed.
" As part of the pilot project, the technology will be rolled out in five selected hospitals in the Czech Republic. Healthcare professionals, accompanied by AI, will evaluate all chest X-rays. "Carebot's artificial intelligence is implemented directly into the system we commonly use for diagnosis. Chest X-rays are often assessed by less experienced doctors. The AI notifies them of even small lesions that might otherwise be missed," said Pavel Struna, Head of the Radiology Department at the Slaný Hospital.
Prof. Robert Lischke, Head of the Surgical Clinic at Motol University Hospital, also views the widespread use of AI in the early detection of lung cancer as crucial for saving human lives: "Early detection of lung cancer is a crucial step in the fight against this persistent disease, allowing patients to undergo surgery, which is essential for successful treatment. Artificial intelligence empowers physicians with a modern tool that can significantly improve our ability to detect it at an early stage, thus improving patients' chances of successful treatment and significantly improving the operability of lung cancer in the Czech Republic."
